![Effects of supervised high-intensity interval training on motivational outcomes in men with prostate cancer undergoing active surveillance: results from a randomized controlled trial | International Journal of Behavioral Nutrition and Physical Activity Effects of supervised high-intensity interval training on motivational outcomes in men with prostate cancer undergoing active surveillance: results from a randomized controlled trial | International Journal of Behavioral Nutrition and Physical Activity](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12966-022-01365-2/MediaObjects/12966_2022_1365_Fig1_HTML.png)
Effects of supervised high-intensity interval training on motivational outcomes in men with prostate cancer undergoing active surveillance: results from a randomized controlled trial | International Journal of Behavioral Nutrition and Physical Activity
![Exercise duRing Active Surveillance for prostatE cancer—the ERASE trial: a study protocol of a phase II randomised controlled trial | BMJ Open Exercise duRing Active Surveillance for prostatE cancer—the ERASE trial: a study protocol of a phase II randomised controlled trial | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/9/7/e026438/F3.large.jpg)
Exercise duRing Active Surveillance for prostatE cancer—the ERASE trial: a study protocol of a phase II randomised controlled trial | BMJ Open
![Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download](https://slideplayer.com/6615222/23/images/slide_1.jpg)
Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download
![Kidney Cancer - ASCO GU 2021 Highlights - Text Module - GUCS 2021 - Oncology - Clinical Care Options Kidney Cancer - ASCO GU 2021 Highlights - Text Module - GUCS 2021 - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/gucs-2021/ea/asco_gu_2021_thumb-31.png?rev=acebf192f906444190d28a91bb1d5023&as=True&h=281&w=500&la=en&hash=963AE6238DD2986A3D766EA025D57EA9A06C5BFD&hash=963AE6238DD2986A3D766EA025D57EA9A06C5BFD)
Kidney Cancer - ASCO GU 2021 Highlights - Text Module - GUCS 2021 - Oncology - Clinical Care Options
![American College of Cardiology on Twitter: "The CLEAR Wisdom trial showed that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with #ASCVD or heterogeneous FH on American College of Cardiology on Twitter: "The CLEAR Wisdom trial showed that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with #ASCVD or heterogeneous FH on](https://pbs.twimg.com/media/D3y0K-mW0AEr5CG.jpg)
American College of Cardiology on Twitter: "The CLEAR Wisdom trial showed that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with #ASCVD or heterogeneous FH on
![High Intensity Training regimen may inhibit prostate cancer growth — ERASE trial - Juta MedicalBrief High Intensity Training regimen may inhibit prostate cancer growth — ERASE trial - Juta MedicalBrief](https://www.medicalbrief.co.za/wp-content/uploads/2021/09/7-MB-Editors-Picks-02-09-2021-1-Exercise-Gym-Man-Intensity-Training-Jump-iStock-1136434170.jpg)
High Intensity Training regimen may inhibit prostate cancer growth — ERASE trial - Juta MedicalBrief
![ESMO 2021: Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update ESMO 2021: Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update](https://www.urotoday.com/images/com-doc-importer/16-esmo-2021/esmo-2021-phase-3-clear-trial-in-advanced-renal-cell-carcinoma-outcomes-in-subgroups-and-toxicity-update/image-0.jpg)
ESMO 2021: Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update
![ASCO 2021: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (RCC): Effect of Subsequent Therapy on Survival Outcomes in the Lenvatinib (LEN) + Everolimus (EVE) Versus Sunitinib (SUN) ASCO 2021: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (RCC): Effect of Subsequent Therapy on Survival Outcomes in the Lenvatinib (LEN) + Everolimus (EVE) Versus Sunitinib (SUN)](https://www.urotoday.com/images/CLEAR_trial.png)
ASCO 2021: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (RCC): Effect of Subsequent Therapy on Survival Outcomes in the Lenvatinib (LEN) + Everolimus (EVE) Versus Sunitinib (SUN)
![Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download](https://slideplayer.com/9/2521450/big_thumb.jpg)
Clinical Trial Results. org The ERASE Trial: Effect of rHDL on Atherosclerosis-Safety and Efficacy Presented at American College of Cardiology Annual Scientific. - ppt download
![A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance | Journal of Urology A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance | Journal of Urology](https://www.auajournals.org/cms/asset/4239f39e-0cb5-4ea9-b212-23b3f1291273/ju.0000000000002334f1.gif)
A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance | Journal of Urology
![ASCO 2021: Health-Related Quality-of-Life Analysis from the Phase 3 CLEAR Trial of Lenvatinib + Pembrolizumab or Everolimus Versus Sunitinib for Patients with Advanced RCC ASCO 2021: Health-Related Quality-of-Life Analysis from the Phase 3 CLEAR Trial of Lenvatinib + Pembrolizumab or Everolimus Versus Sunitinib for Patients with Advanced RCC](https://www.urotoday.com/images/ASCO_IV_Q3W.png)